Drug Trial Radar · NCT01532648
Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)
Last checked: Nov 20, 2026Latest source record: Sep 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
510
Actual
Start
Jan 27, 2012
Primary completion
Oct 2, 2013
Study completion Oct 2, 2013
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 14, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to compare the efficacy and safety of budesonide MMX 9 mg versus placebo as add-on therapy to an existing oral 5-ASA regimen for the induction of remission in participants with active mild or moderate ulcerative colitis (UC).
Conditions
- Ulcerative Colitis
Interventions
Budesonide MMX®Drug
Oral tablet taken daily in the morning after breakfast.
PlaceboDrug
Matching budesonide MMX placebo oral tablet taken daily in the morning after breakfast.
5-ASADrug
Acceptable oral 5-ASA medications to be received during the study include: * Asacol®, Asacol® HD, Lialda®, Pentasa® (generic: mesalamine), minimum daily dose ≥2.4 grams (g) * Azulfidine® (generic: sulfasalazine), minimum daily dose ≥4.0 g * Dipentum® (generic: olsalazine), minimum daily dose ≥2.0 g * Colazal®, Colazide® (generic: balsalazide), minimum daily dose ≥6.75 g
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Achieved Clinical Remission at Day 56Time frame: Baseline up to Day 56
Locations
114 sites in 11 countries. Site status is shown where the registry gives one.
Santarus Clinical Investigational Site 1043
Anaheim, California
Santarus Clinical Investigational Site 1071
Lakewood, California
Santarus Clinical Investigational Site 1003
San Diego, California
Santarus Clinical Investigational Site 1063
Littleton, Colorado
Santarus Clinical Investigational Site 1028
Bristol, Connecticut
Santarus Clinical Investigational Site 1035
Boynton Beach, Florida
Santarus Clinical Investigational Site 1045
Jacksonville, Florida
Santarus Clinical Investigational Site 1001
Largo, Florida
Santarus Clinical Investigational Site 1024
Maitland, Florida
Santarus Clinical Investigational Site 1029
Port Orange, Florida
Santarus Clinical Investigational Site 1010
Winter Park, Florida
Santarus Clinical Investigational Site 1002
Zephyrhills, Florida
Santarus Clinical Investigational Site 1050
Decatur, Georgia
Santarus Clinical Investigational Site 1075
Chicago, Illinois
Santarus Clinical Investigational Site 1065
Oak Lawn, Illinois
Santarus Clinical Investigational Site 1058
Indianapolis, Indiana
Santarus Clinical Investigational Site 1032
Shreveport, Louisiana
Santarus Clinical Investigational Site 1044
Annapolis, Maryland
Santarus Clinical Investigational Site 1016
Chesterfield, Michigan
Santarus Clinical Investigational Site 1081
Novi, Michigan
Santarus Clinical Investigational Site 1015
Wyoming, Michigan
Santarus Clinical Investigational Site 1068
Ypsilanti, Michigan
Santarus Clinical Investigational Site 1074
Rochester, Minnesota
Santarus Clinical Investigational Site 1061
Lebanon, New Hampshire
Santarus Clinical Investigational Site 1021
Cheektowaga, New York
Santarus Clinical Investigational Site 1072
Great Neck, New York
Santarus Clinical Investigational Site 1031
New York, New York
Santarus Clinical Investigational Site 1073
Wilmington, North Carolina
Santarus Clinical Investigational Site 1080
Cincinnati, Ohio
Santarus Clinical Investigational Site 1078
Cleveland, Ohio
Santarus Clinical Investigational Site 1082
Dayton, Ohio
Santarus Clinical Investigational Site 1064
Lancaster, Pennsylvania
Santarus Clinical Investigational Site 1006
Sayre, Pennsylvania
Santarus Clinical Investigational Site 1059
Austin, Texas
Santarus Clinical Investigational Site 1039
Houston, Texas
Santarus Clinical Investigational Site 1005
Pasadena, Texas
Santarus Clinical Investigational Site 1014
Lancaster, Utah
Santarus Clinical Investigational Site 1038
Chesapeake, Virginia
Santarus Clinical Investigational Site 1025
Christiansburg, Virginia
Santarus Clinical Investigational Site 4003
Pleven, Bulgaria
Showing 40 of 114 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.